Drugs / HA antigens
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03293732 | Nov 2012 → Mar 2013 | influenza | Advagene Biopharma Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HA antigens | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03293732 ↗ |
| Modality | Vaccine | “intranasal vaccine containing the trivalent influenza HA antigen” PMID 30837170 ↗ Mar 2019 |
| Route | Intranasal | “The vaccine was intranasally administered on Days 0 and 7.” PMID 30837170 ↗ Mar 2019 |